UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 134

Sortiert nach

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

Cancer science, 2020-12, Vol.111 (12), p.4510-4525

2020

Link zum Volltext

Verfügbarkeit prüfen

Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST

Blood, 2011-01, Vol.117 (2), p.459-469

2011

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)

Clinical cancer research, 2022-10, Vol.28 (19), p.OF1-4231

2022

Link zum Volltext

Verfügbarkeit prüfen

Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer

PloS one, 2020-10, Vol.15 (10), p.e0236503-e0236503

2020

Link zum Volltext

Verfügbarkeit prüfen

Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity

Cancer cell, 2008-05, Vol.13 (5), p.385-393

2008

Link zum Volltext

Verfügbarkeit prüfen

Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer

Scientific reports, 2021-08, Vol.11 (1), p.16122-16122, Article 16122

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer

PloS one, 2022-04, Vol.17 (4), p.e0267362-e0267362

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer

Scientific reports, 2022-08, Vol.12 (1), p.13566-13566, Article 13566

2022

Link zum Volltext

Verfügbarkeit prüfen

Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs

International journal of molecular sciences, 2022-09, Vol.23 (19), p.11353

2022

Link zum Volltext

Verfügbarkeit prüfen

Pneumatosis intestinalis induced by targeted therapy

Postgraduate medical journal, 2022-01, Vol.98 (1155), p.10

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell‐free DNA from non‐small‐cell lung cancer patients with leptomeningeal metastases

Thoracic cancer, 2023-05, Vol.14 (14), p.1251-1259

2023

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

JTO clinical and research reports, 2022-06, Vol.3 (6), p.100332-100332, Article 100332

2022

Link zum Volltext

Verfügbarkeit prüfen

Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell-derived organoids

Thoracic cancer, 2023-09, Vol.14 (25), p.2591-2600

2023

Link zum Volltext

Verfügbarkeit prüfen

An Open‐Label, Single‐Arm, Two‐Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas

The oncologist (Dayton, Ohio), 2020-05, Vol.25 (5), p.e782-e788

2020

Link zum Volltext

Verfügbarkeit prüfen

Functional outcomes and survival after surgical stabilization for inoperable non-small-cell lung cancer with spinal metastasis of the thoracic and lumbar spines: a retrospective comparison between epidermal growth factor receptor-tyrosine kinase inhibitor and platinum-based chemotherapy groups

Spinal cord, 2020-02, Vol.58 (2), p.194-202

2020

Link zum Volltext

Verfügbarkeit prüfen

Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation

Journal of the Formosan Medical Association, 2020-09, Vol.119 (9), p.1439-1441

2020

Link zum Volltext

Verfügbarkeit prüfen

Cytology-Based Specimen Triage for Epidermal Growth Factor Receptor Mutation Testing of Malignant Pleural Effusions in Non-Small Cell Lung Cancer

Frontiers in oncology, 2022-01, Vol.12, p.810124-810124

2022

Link zum Volltext

Verfügbarkeit prüfen

Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI

Targeted oncology, 2020-08, Vol.15 (4), p.503-512

2020

Link zum Volltext

Verfügbarkeit prüfen

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

Clinical cancer research, 2005-05, Vol.11 (10), p.3750-3757

2005

Link zum Volltext

Verfügbarkeit prüfen

Cerebrospinal fluid as a medium of liquid biopsy in the management of patients with non-small-cell lung cancer having central nervous system metastasis

Frontiers in bioscience (Landmark. Print), 2021-12, Vol.26 (12), p.1679-1688

2021

Link zum Volltext

Verfügbarkeit prüfen

Salvage surgery after definitive chemoradiotherapy through VATS for an initial unresectable locally advanced lung cancer: an alternative consolidative modality to radiotherapy?

Surgical case reports, 2021-06, Vol.7 (1), p.1-8, Article 138

2021

Link zum Volltext

Verfügbarkeit prüfen

Progressive Pleural Effusion as an Immune-Related Adverse Event in NSCLC: A Case Report

JTO clinical and research reports, 2021-05, Vol.2 (5), p.100156, Article 100156

2021

Link zum Volltext

Verfügbarkeit prüfen

Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis

Targeted oncology, 2021-03, Vol.16 (2), p.207-214

2021

Link zum Volltext

Verfügbarkeit prüfen

Never Say No to Never-Smokers

Journal of thoracic oncology, 2023-06, Vol.18 (6), p.689-693

2023

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan

Journal of the Formosan Medical Association, 2020-12, Vol.119 (12), p.1817-1826

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 134

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(120)
Mit Volltextzugriff
(132)

Publikationsform

Sprache

Englisch
(132)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(84)
Life Sciences & Biomedicine
(80)
Humans
(71)
Oncology
(57)
Lung Neoplasms - Drug Therapy
(39)
Female
(34)
Male
(32)
Middle Aged
(32)
Aged
(31)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(31)
Respiratory System
(30)
Adult
(28)
Lung Cancer
(28)
Mutation
(25)
Aged, 80 And Over
(24)
Lung Neoplasms - Genetics
(24)
Lung Neoplasms - Pathology
(23)
Patients
(18)
Carcinoma, Non-Small-Cell Lung - Genetics
(17)
Biological And Medical Sciences
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST

Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)

Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer

Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity

Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer

Real-world evidence of the intrinsic limitations of PCR-based EGFR mutation assay in non-small cell lung cancer

Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs

Pneumatosis intestinalis induced by targeted therapy

Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell‐free DNA from non‐small‐cell lung cancer patients with leptomeningeal metastases

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell-derived organoids

An Open‐Label, Single‐Arm, Two‐Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas

Functional outcomes and survival after surgical stabilization for inoperable non-small-cell lung cancer with spinal metastasis of the thoracic and lumbar spines: a retrospective comparison between epidermal growth factor receptor-tyrosine kinase inhibitor and platinum-based chemotherapy groups

Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation

Cytology-Based Specimen Triage for Epidermal Growth Factor Receptor Mutation Testing of Malignant Pleural Effusions in Non-Small Cell Lung Cancer

Post-Progression Survival in Secondary EGFR T790M-Mutated Non-Small-Cell Lung Cancer Patients With and Without Osimertinib After Failure of a Previous EGFR TKI

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

Cerebrospinal fluid as a medium of liquid biopsy in the management of patients with non-small-cell lung cancer having central nervous system metastasis

Salvage surgery after definitive chemoradiotherapy through VATS for an initial unresectable locally advanced lung cancer: an alternative consolidative modality to radiotherapy?

Progressive Pleural Effusion as an Immune-Related Adverse Event in NSCLC: A Case Report

Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis

Never Say No to Never-Smokers

Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan

Suchergebnisse filtern